Biogen BIIB Royalty Attributed To OCREVUS — Total Revenue

Other product segments

Similar metrics at other companies

GERNRoyalties — Total revenues

$66K-60.5%

RIGLRoyalty — Revenue recognized

$1.8M+28.6%

NVAXRoyalties — Total Revenue

$3.52M—

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

RARECollaboration And Royalty — Revenue

$93M-9.7%

INCYOLUMIANT Royalty Revenues — Total revenues

$36.41M+18.2%

Questions, answered.

What is Biogen's royalty attributed to OCREVUS — total revenue?

Biogen (BIIB) reported royalty attributed to OCREVUS — total revenue of $317.2M in Q1 2026.

How has Biogen's royalty attributed to OCREVUS — total revenue changed year-over-year?

Biogen's royalty attributed to OCREVUS — total revenue increased by 9.8% year-over-year, from $288.8M to $317.2M.

What is the long-term trend for Biogen's royalty attributed to OCREVUS — total revenue?

Over 4 years (2021 to 2025), Biogen's royalty attributed to OCREVUS — total revenue has grown at a 9.3% compound annual growth rate (CAGR), from $991.7M to $1.41B.

What does royalty attributed to OCREVUS — total revenue mean?

This metric represents the total revenue recognized by the company from royalty payments generated by the sales of OCREVUS, a therapeutic product marketed by a collaborative partner. It reflects the financial benefit derived from intellectual property licensing and commercialization agreements where the company holds a stake in the product's market performance. This revenue stream is a critical component of the company's non-operating or collaborative income portfolio.